Clinical Trials Logo

Filter by:
NCT ID: NCT06363461 Recruiting - Atopic Dermatitis Clinical Trials

Study of TDM-180935 in Atopic Dermatitis Patients

Start date: April 13, 2024
Phase: Phase 2
Study type: Interventional

Randomized, Vehicle-controlled, Parallel Group Study of TDM-180935 in Atopic Dermatitis Patients

NCT ID: NCT06363240 Recruiting - Solar Lentigo Clinical Trials

Evaluation of Broadband Light Treatment for Solar Lentigines

Start date: March 12, 2024
Phase: N/A
Study type: Interventional

Broadband light treatment for Solar Lentigines

NCT ID: NCT06362941 Recruiting - Hair Thinning Clinical Trials

Evaluation of an Oral Hair Supplement to Improve Hair Strength and Support Growth in Women and Men

Start date: May 20, 2024
Phase: N/A
Study type: Interventional

A single-center, open-label, prospective study to demonstrate the efficacy of an oral supplement to improve the strength and support the growth of thinning hair in men and women with self-perceived hair thinning.

NCT ID: NCT06362759 Recruiting - Clinical trials for Chronic Kidney Diseases

A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP

TRANQUILITY
Start date: May 15, 2024
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 in participants with chronic kidney disease and elevated hs-CRP.

NCT ID: NCT06362642 Recruiting - Healthy Volunteers Clinical Trials

A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants

Start date: March 28, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the effect of PC14586 pharmacokinetics when co administered with itraconazole in healthy participants.

NCT ID: NCT06362369 Recruiting - Colorectal Cancer Clinical Trials

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Start date: May 20, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b

NCT ID: NCT06362356 Recruiting - Clinical trials for Hypertensive Disorder of Pregnancy

Microbial Metabolites and Outcomes of Pregnancy Study

MMOPS
Start date: March 5, 2024
Phase:
Study type: Observational

Emerging data connect diet, the gut microbiota and its metabolites in cardiometabolic disease. Hypertensive disorders of pregnancy (HDP) are common and are a leading cause of maternal and neonatal morbidity. HDP likely share similar pathophysiology as cardiometabolic disease in non-pregnant people with a yet unrevealed role of diet and the gut microbiota, including systemic inflammation and endothelial dysfunction. Despite high biological plausibility that nutrition, the gut microbiota and its metabolites may play a role in health and disease in pregnancy, there is a paucity of data regarding these associations, thus limiting advancement of the field. Similar to the proposed pathogenesis for diet, gut microbiota and the microbial metabolite trimethylamine-N-oxide (TMAO) in cardiovascular disease, we hypothesize that the interplay between maternal diet, the gut microbiota and its associated microbial metabolites play a mechanistic role in HDP. We propose to test this hypothesis in a racially-diverse US cohort to determine association with adverse pregnancy outcomes, specifically future development of HDP. We propose to prospectively collect plasma and urine TMAO throughout pregnancy from a cohort of 200 pregnant participants. Through 1) characterizing plasma and urine TMAO levels across each trimester of pregnancy, and 2) assessment of this microbial metabolite as a predictor of development of HDP, we have the potential to identify a biomarker that would allow us to identify people at risk of HDP early in pregnancy and provide new opportunities for therapeutic interventions to improve maternal and neonatal outcomes.

NCT ID: NCT06361875 Recruiting - Clinical trials for Influenza Immunization

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Start date: April 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different formulations of Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) (MRT5421, MRT5424, and MRT5429) compared to an active control (QIV- standard dose (SD), QIV- high dose (HD) [adults ≥ 65 years of age only], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.

NCT ID: NCT06361836 Recruiting - Clinical trials for Hidradenitis Suppurativa

Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa

Regulate-HS
Start date: June 2024
Phase: Phase 1
Study type: Interventional

This study will test the safety and effects of SBT777101 when given as a single dose to subjects with hidradenitis suppurativa. Increasing dose levels will be given after the safety at lower dose levels is shown.

NCT ID: NCT06361498 Recruiting - Gastrostomy Clinical Trials

Ultrasound for Evaluation of Percutaneous G-tube Position

Start date: April 30, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare using ultrasound imaging to look at the position of the gastrostomy tube (GT) against fluoroscopic imaging in pediatric patients who had a recent GT tube replacement. The main questions it aims to answer are: - If ultrasound is just as accurate as fluoroscopy to assess the GT position. - If ultrasound takes less time than fluoroscopy to assessing the GT position. Participants will be imaging using ultrasound to assess GT positioning before their standard of care fluoroscopic imaging.